MiR-150 acts in vitro as tumor suppressor by activating apoptosis and inhibiting proliferation in primary AML cells, as well as in vivo by the reduction of human leukemia engraftments in nude mice through the targeting of the genes eukaryotic translation initiation factor 4B (EIF4B), forkhead box O4 (FOXO4), protein kinase C alpha (PRKCA), and tet methylcytosine dioxygenase 3 (TET3) [151]. The gene discussed is PRKCA; the disease is acute myeloid leukemia.